In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed. This study evaluates cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable softtissue disease who have progressed after treatment with one prior NHT. Also Read: Bristol Myers, Exelixis Reveal 4-Year Follow-Up Re ...

Exelixis, Inc. (NASDAQ:EXEL) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer Amy Peterson - Executive Vice President, Product Development, Medical Affairs and Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - Executive Vice President of Commerci ...

Exelixis (EXEL) reported $637.18 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 35.6%. EPS of $0.84 for the same period compares to $0.31 a year ago. The reported revenue represents a surprise of +36.09% over the Zacks Consensus Estimate of $468.21 million. With the consensus EPS estimate being $0.37, the EPS surprise was +127.03%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

Exelixis (EXEL) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 127.03%. A quarter ago, it was expected that this drug developer would post earnings of $0.28 per share when it actually produced earnings of $0.17, delivering a surprise of -39.29%. Over the last four quarters, the compa ...

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 million - - GAAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of $0.84 - - U.S. Food and Drug Administration (FDA) Acc ...

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Estimate Revisions Trend The earnings report, which is expected to be released on August 6, 2024, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. This drug ...

Exelixis, Inc. (EXEL) entered into a settlement agreement with Cipla, which was looking to market a generic version of Cabometyx (cabozantinib). Cabometyx is Exelixis' lead drug. The settlement agreement resolves two patent litigations brought by Exelixis in response to Cipla's abbreviated new drug application (ANDA). The ANDA is seeking approval to market generic versions of Cabometyx tablets prior to the expiration of the applicable patents. The first case relates to Cipla's ANDA for a 60 mg cabozantinib ...

These stocks are both experts in their respective fields.Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field could deliver outsized returns. However, there are other exciting investment opportunities out there. Consider Renaissance Technologies, a hedge fund headed by Jim Simons. The fund's holdings feature several healthcare stocks. That includes two notable drugma ...

Have you assessed how the international operations of Exelixis (EXEL) performed in the quarter ended March 2024? For this drug developer, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importan ...

Exelixis, Inc. (EXEL) reported lower-than-expected results for the first quarter. Its shares fell 7% in after-hours trading following the announcement.EXEL recorded earnings of 17 cents per share, which missed the Zacks Consensus Estimate of 28 cents. The company registered adjusted earnings of 16 cents per share in the first quarter of 2023.Including stock-based compensation expense, EPS was 12 cents, flat year over year.Net revenues were $425.2 million, which lagged the Zacks Consensus Estimate of $468 mi ...